Table II.
Characteristics of patients with stage IIIa and IIIb colorectal cancer.
| A, Stage IIIa colorectal cancer | ||||
|---|---|---|---|---|
| Variable | Total number of patients (n=28) | HLA-A*2402 (n=15) | non-HLA-A*2402 2402 (n=13) | P-value |
| Age, median (range), years | 64 (37–80) | 66 (37–74) | 63 (50–80) | n.s. |
| Sex, n (%) | n.s. | |||
| Male | 12 (43%) | 7 (47%) | 5 (38%) | |
| Female | 16 (57%) | 8 (53%) | 8 (62%) | |
| Number of vaccination, median (range) | 30 (30–30) | 30 (30–30) | 30 (30–30) | n.s. |
| Colon/rectum, n (%) | n.s. | |||
| Colon | 18 (64%) | 12 (80%) | 6 (46%) | |
| Rectum | 10 (36%) | 3 (20%) | 7 (54%) | |
| Location of primary tumor, n (%) | n.s. | |||
| Right | 8 (29%) | 4 (27%) | 4 (31%) | |
| Left | 20 (71%) | 11 (73%) | 9 (69%) | |
| B, Stage IIIb colorectal cancer | ||||
| Variable | Total number of patients (n=28) | HLA-A*2402 (n=15) | non-HLA-A*2402 2402 (n=13) | P-value |
| Age, median (range), years | 61 (39–80) | 60 (39–76) | 80 (47–80) | n.s. |
| Sex, n (%) | n.s. | |||
| Male | 8 (50%) | 7 (54%) | 1 (33%) | |
| Female | 8 (50%) | 6 (46%) | 2 (67%) | |
| Number of vaccination, median (range) | 30 (21–30) | 30 (21–30) | 30 (30–30) | n.s. |
| Colon/rectum, n (%) | n.s. | |||
| Colon | 6 (38%) | 5 (38%) | 1 (33%) | |
| Rectum | 10 (62%) | 8 (62%) | 2 (67%) | |
| Location of primary tumor, n (%) | n.s. | |||
| Right | 4 (25%) | 3 (23%) | 1 (33%) | |
| Left | 12 (75%) | 10 (77%) | 2 (67%) | |
HLA-A, human leukocyte antigen-A; n.s., not significant.